152 related articles for article (PubMed ID: 38880199)
41. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris.
Li M; Han J; Lu Z; Li H; Zhu K; Cheng R; Jiao Q; Zhang C; Zhu C; Zhuang Y; Wang Y; Shi J; Guo Y; Wu R; Yao Z
J Invest Dermatol; 2013 Nov; 133(11):2637-2639. PubMed ID: 23863864
[No Abstract] [Full Text] [Related]
42. Clinical analysis of generalized pustular psoriasis in Chinese patients: A retrospective study of 110 patients.
Zheng J; Chen W; Gao Y; Chen F; Yu N; Ding Y; Liu N
J Dermatol; 2021 Sep; 48(9):1336-1342. PubMed ID: 34018629
[TBL] [Abstract][Full Text] [Related]
43. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
44. Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
Ali F; Smith CH; Mahil SK
Br J Dermatol; 2023 Feb; 188(3):328-329. PubMed ID: 36763745
[No Abstract] [Full Text] [Related]
45. A case of generalized pustular psoriasis with discrepant resolution time between pustules and erythema after treatment with spesolimab.
Matsuo M; Niwa H; Onishi H; Iwata H
J Dermatol; 2024 Apr; 51(4):e127-e128. PubMed ID: 37955351
[No Abstract] [Full Text] [Related]
46. Generalized pustular psoriasis with a novel mutation of interleukin-36 receptor antagonist, responding to methotrexate.
Teoh YL; Tay YK
JAAD Case Rep; 2015 Mar; 1(2):51-3. PubMed ID: 27051681
[No Abstract] [Full Text] [Related]
47. Severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36-directed monoclonal antibody.
Mateeva V; Vasilev P; Gospodinova K; Gincheva V; Shahid M; Kostova P; Lukanov T; Yordanova I
J Dtsch Dermatol Ges; 2024 May; 22(5):696-699. PubMed ID: 38619312
[No Abstract] [Full Text] [Related]
48. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment.
Rivera-Díaz R; Daudén E; Carrascosa JM; Cueva P; Puig L
Dermatol Ther (Heidelb); 2023 Mar; 13(3):673-688. PubMed ID: 36635445
[TBL] [Abstract][Full Text] [Related]
49. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives.
Iznardo H; Puig L
Expert Rev Clin Immunol; 2021 Feb; 17(2):187-199. PubMed ID: 33538202
[No Abstract] [Full Text] [Related]
50. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Mrowietz U; Burden AD; Pinter A; Reich K; Schäkel K; Baum P; Datsenko Y; Deng H; Padula SJ; Thoma C; Bissonnette R
Dermatol Ther (Heidelb); 2021 Apr; 11(2):571-585. PubMed ID: 33661508
[TBL] [Abstract][Full Text] [Related]
51. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis.
Lan Y; Wu X; Zhong X; Song P; Liu L; Liu Y; Ai X; Han C; Zhang Z
Exp Dermatol; 2024 Feb; 33(2):e15026. PubMed ID: 38414093
[TBL] [Abstract][Full Text] [Related]
52. Generalized Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, and Other Pustular Reactions: A Clinical Review.
Gössinger E; Dodiuk-Gad R; Mühleisen B; Oon HH; Oh CC; Maul JT; Navarini AA
Dermatol Clin; 2024 Apr; 42(2):317-328. PubMed ID: 38423690
[TBL] [Abstract][Full Text] [Related]
53. Spesolimab for the treatment of generalized pustular psoriasis: real life experience.
Dattola A; Taliano A; Rallo A; Pellacani G; Richetta AG
Ital J Dermatol Venerol; 2024 Feb; 159(1):61-62. PubMed ID: 38226936
[No Abstract] [Full Text] [Related]
54. Spesolimab use in treatment of pyoderma gangrenosum.
Guénin SH; Khattri S; Lebwohl MG
JAAD Case Rep; 2023 Apr; 34():18-22. PubMed ID: 36936866
[No Abstract] [Full Text] [Related]
55. IL-17A-driven psoriasis is critically dependent on IL-36 signaling.
Fischer B; Kübelbeck T; Kolb A; Ringen J; Waisman A; Wittmann M; Karbach S; Kölsch SM; Kramer D
Front Immunol; 2023; 14():1256133. PubMed ID: 38162658
[TBL] [Abstract][Full Text] [Related]
56. Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series.
Bellinato F; Gisondi P; Dattola A; Richetta AG; Costanzo A; Valenti M; De Simone C; Marzano AV; Zussino M; Pezzolo E; Nacca M; Pellacani G; Girolomoni G
J Eur Acad Dermatol Venereol; 2024 May; 38(5):e437-e439. PubMed ID: 38084869
[No Abstract] [Full Text] [Related]
57. Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice.
Balato A; Ambrogio F; Burlando M; Carrera CG; Chiricozzi A; Esposito M; Piaserico S; Teoli M; Gisondi P
Dermatol Ther (Heidelb); 2024 Jan; 14(1):5-13. PubMed ID: 38048034
[No Abstract] [Full Text] [Related]
58. Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review.
Cardenas-de la Garza JA; Zazueta-López RM; Garza-Elizondo AK; Flores-Gutierrez DP; Welsh E
Clin Exp Dermatol; 2024 Feb; 49(3):286-288. PubMed ID: 37966307
[No Abstract] [Full Text] [Related]
59. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.
Iznardo H; Puig L
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919434
[TBL] [Abstract][Full Text] [Related]
60. Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.
Hackley M; Thampy D; Waseh S; Feldman SR; Blauvelt A; Weinberg JM; Schwartzman S; Liao W; Prussick R; Cohen JM; Hsu S;
J Am Acad Dermatol; 2024 Feb; 90(2):408-410. PubMed ID: 37821053
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
